A corporate venture arm of a global organization invests across a wide range of financing stages, from Seed through IPO, with flexible initial check sizes and the ability to provide follow-on capital. The firm primarily focuses on opportunities in the United States, while also evaluating companies in Europe and Asia. The firm does not lead investment rounds and prefers to participate alongside an established lead investor. Depending on the investment size and structure, the firm may take an observer or board seat. The firm invests strictly through equity and does not operate an equity-for-services model.
In parallel to its investment activities, the broader organization operates a global support initiative that collaborates with accelerators, venture capital firms, and incubators to provide startups with access to development platforms, technical resources, and infrastructure to accelerate biologics and vaccine programs. Participation in this ecosystem can provide companies with non-dilutive support and development advantages.
The firm invests across a broad range of biologics and therapeutic modalities, including antibody-based therapies, protein therapeutics, vaccines, and nucleic acid-based approaches such as DNA and mRNA therapeutics. The firm is also open to orphan drug opportunities. The firm does not invest in cell and gene therapy.
From a company and management team perspective, the firm is open to working with both first-time and experienced founders but values teams with strong support networks. The firm seeks collaborative founders who are receptive to strategic input and partnership. The firm requires a lead investor to be in place prior to investing and typically participates as a strategic co-investor.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.
Next Phase Newsletter 